Nattakorn Dhiantravan

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

Michael S. Hofman, Louise Emmett, Shahneen Sandhu et al. · The Lancet · 2021 · 1.1K citations

Medicine, Oncology, Pharmacology +12

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

Michael S. Hofman, Louise Emmett, Shahneen Sandhu et al. · The Lancet Oncology · 2023 · 199 citations

Medicine, Oncology, Pharmacology +16

Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study

Arun Azad, Mathias Bressel, Hsiang Tan et al. · The Lancet Oncology · 2024 · 111 citations

Medicine, Oncology, Urology +12

Administering [177Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study

Renu Eapen, James P Buteau, Price Jackson et al. · European Urology · 2023 · 84 citations

Medicine, Surgery, Urology +12

UpFrontPSMA: a randomized phase 2 study of sequential ¹⁷⁷ Lu‐PSMA‐617 and docetaxel vs docetaxel in metastatic hormone‐naïve prostate cancer (clinical trial protocol)

Nattakorn Dhiantravan, Louise Emmett, Anthony M. Joshua et al. · British Journal of Urology · 2021 · 63 citations · Full text

Medicine, Oncology, Pharmacotherapy +17